To ensure that Cancer Moonshot goals and approaches were grounded in the best science, NCI convened a Blue Ribbon Panel of scientific experts as a working group to the National Cancer Advisory Board. In September of 2016, the Blue Ribbon Panel presented a final report outlining 10 research recommendations. These represent areas that are well positioned to accelerate progress in cancer prevention, diagnosis, treatment, and care.
The following research categories align with these 10 recommendations:
| Research Category | Amount1 |
|---|---|
| Network for Direct Patient Engagement | $15,120,649 |
| Cancer Immunotherapy Translational Science Network | $6,338,811 |
| Therapeutic Target Identification to Overcome Drug Resistance | $1,142,240 |
| A National Cancer Data Ecosystem for Sharing and Analysis | $0 |
| Fusion Oncoproteins in Childhood Cancers | $0 |
| Minimize Cancer Treatment’s Debilitating Side Effects | $680,509 |
| Prevention and Early Detection: Implementation of Evidence-Based Approaches | $18,198,244 |
| Retrospective Analysis of Biospecimens from Patients Treated with Standard of Care | $0 |
| Generation of Human Tumor Atlases | $47,604,372 |
| Development of New Enabling Cancer Technologies | $0 |
| Other Cancer Moonshot Priority Activities (e.g., Partnership for Accelerating Cancer Therapies) | $24,518,528 |
| Total | $113,603,353 |
| 1 Includes new obligations and recoveries from fiscal years 2017, 2018, 2019, 2020, 2021, 2022, and 2023 carryover accounts. | |